Repurposing clinical molecule ebselen to combat drug resistant pathogens

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Thangamani, Shankar ^a   Younis, Waleed ^a   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; CLINDAMYCIN; EBSELEN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; ORGANOSELENIUM DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIUM ISOLATE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; CYTOTOXICITY; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG REPOSITIONING; ENTEROCOCCUS; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIC90; MITOCHONDRIAL RESPIRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN SYNTHESIS; STAPHYLOCOCCUS; STREPTOCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; CELL LINE; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; GRAM POSITIVE BACTERIUM; INTRACELLULAR SPACE; MICROBIOLOGY; ORGANELLE BIOGENESIS; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; AZOLES; CAENORHABDITIS ELEGANS; CELL LINE; DRUG REPOSITIONING; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; GRAM-POSITIVE BACTERIA; INTRACELLULAR SPACE; MICE; ORGANELLE BIOGENESIS; ORGANOSELENIUM COMPOUNDS; PROTEIN BIOSYNTHESIS; TRANSCRIPTION, GENETIC;

EID: 84941889409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133877     Document Type: Article

References (49)

1. Mohammad H, Mayhoub AS, Cushman M, Seleem MN. Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant Staphylococci. The Journal of antibiotics. 2014.
2. Thangamani S, Mohammad H, Younis W, Seleem MN. Drug Repurposing for the Treatment of Staphylococcal Infections. Current pharmaceutical design. 2015.
3. Younis W, Thangamani S, Seleem MN. Repurposing Non-antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections. Current pharmaceutical design. 2015.
4. Thangamani S, Younis W, Seleem MN. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections. Scientific reports. 2015; 5:11596. doi:10.1038/srep11596 PMID: 26111644.
5. Austin CP, Brady LS, Insel TR, Collins FS. NIH Molecular Libraries Initiative. Science. 2004; 306 (5699):1138-9. PMID: 15542455.
6. Schewe T. Molecular actions of ebselen-an antiinflammatory antioxidant. General pharmacology. 1995; 26(6):1153-69. PMID: 7590103.
7. Nozawa R, Yokota T, Fujimoto T. Susceptibility of methicillin-resistant Staphylococcus aureus to the selenium-containing compound 2-phenyl-1, 2-benzoisoselenazol-3(2H)-one (PZ51). Antimicrobial agents and chemotherapy. 1989; 33(8):1388-90. PMID: 2802564.
8. Lu J, Vlamis-Gardikas A, Kandasamy K, Zhao R, Gustafsson TN, Engstrand L, et al. Inhibition of bacterial thioredoxin reductase: An antibiotic mechanism targeting bacteria lacking glutathione. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2013; 27 (4):1394-403.
9. Favrot L, Grzegorzewicz AE, Lajiness DH, Marvin RK, Boucau J, Isailovic D, et al. Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen. Nature communications. 2013; 4:2748. doi:10.1038/ncomms3748 PMID: 24193546.
10. Chan G, Hardej D, Santoro M, Lau-Cam C, Billack B. Evaluation of the antimicrobial activity of ebselen: role of the yeast plasma membrane H+-ATPase. Journal of biochemical and molecular toxicology. 2007; 21(5):252-64. PMID: 17912695.
11. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7. CLSI, Wayne, PA. 2007.
12. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003; 47(7):2283-92. PMID: 12821480.
13. Alajlouni RA, Seleem MN. Targeting listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids. Nucleic acid therapeutics. 2013; 23(5):363-7. doi:10.1089/nat.2013.0426 PMID: 23859300.
14. Cohen DJ, Newman E, Iqbal S, Chang RY, Potmesil M, Ryan T, et al. Postoperative intraperitoneal 5- fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. Annals of surgical oncology. 2012; 19(2):478- 85. doi:10.1245/s10434-011-1940-8 PMID: 21769462.
15. Morones-Ramirez JR, Winkler JA, Spina CS, Collins JJ. Silver enhances antibiotic activity against gram-negative bacteria. Science translational medicine. 2013; 5(190):190ra81.
16. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochimica et biophysica acta. 2009; 1794(5):808-16. doi:10.1016/j.bbapap.2008.11.005 PMID: 19100346.
17. Nakae T. The problems in the outer membrane permeability and the antibiotic resistance of Pseudomonas aeruginosa. The Kitasato archives of experimental medicine. 1991; 64(2-3):115-21. PMID: 1667326.
18. Li XZ, Plesiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clinical microbiology reviews. 2015; 28(2):337-418. doi:10.1128/CMR.00117-14 PMID: 25788514.
19. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2003; 23(7):916-24. PMID: 12885104.
20. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. The Journal of antimicrobial chemotherapy. 2009; 64(3):441-6. doi:10.1093/jac/dkp241PMID: 19608582.
21. Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends in microbiology. 2009; 17(2):59-65. doi:10.1016/j.tim.2008.11.005 PMID: 19208480.
22. Ellington JK, Harris M, Webb L, Smith B, Smith T, Tan K, et al. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. The Journal of bone and joint surgery British volume. 2003; 85(6):918-21. PMID: 12931819.
23. Fowler VG Jr., Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. Staphylococcus aureus endocarditis: A consequence of medical progress. Jama. 2005; 293(24):3012-21. PMID: 15972563.
24. Ellington JK, Harris M, Hudson MC, Vishin S, Webb LX, Sherertz R. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2006; 24(1):87-93.
25. Seleem MN, Jain N, Pothayee N, Ranjan A, Riffle JS, Sriranganathan N. Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline. FEMS microbiology letters. 2009; 294(1):24-31. doi:10.1111/j.1574-6968.2009.01530.x PMID: 19493005.
26. Seleem MN, Munusamy P, Ranjan A, Alqublan H, Pickrell G, Sriranganathan N. Silica-antibiotic hybrid nanoparticles for targeting intracellular pathogens. Antimicrobial agents and chemotherapy. 2009; 53 (10):4270-4. doi:10.1128/AAC.00815-09 PMID: 19667284.
27. Soofi MA, Seleem MN. Targeting essential genes in Salmonella enterica serovar typhimurium with antisense peptide nucleic acid. Antimicrobial agents and chemotherapy. 2012; 56(12):6407-9doi:10.1128/AAC.01437-12 PMID: 23006748.
28. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemoth. 1996; 38(5):865-9.
29. Peltola H, Paakkonen M, Kallio P, Kallio MJT. Bad Bugs, No Drugs: No ESCAPE Revisited Reply. Clinical Infectious Diseases. 2009; 49(6):993.
30. Stevens DL, Ma YS, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis. 2007; 195(2):202-11. PMID: 17191165.
31. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, et al. Effects of Linezolid on Suppressing In Vivo Production of Staphylococcal Toxins and Improving Survival Outcomes in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia. J Infect Dis. 2013; 208 (1):75-82. doi:10.1093/infdis/jit129 PMID: 23532096.
32. Otto MP, Martin E, Badiou C, Lebrun S, Bes M, Vandenesch F, et al. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemoth. 2013; 68(7):1524-32.
33. Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G. Linezolid Is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA Class II Transgenic Mice. Antimicrobial agents and chemotherapy. 2012; 56(10):5401-5doi:10.1128/AAC.01080-12 PMID: 22850509.
34. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clinical microbiology reviews. 2002; 15(1):95-110. PMID: 11781269.
35. Diep BA, Equils O, Huang DB, Gladue R. Linezolid effects on bacterial toxin production and host immune response: review of the evidence. Current therapeutic research, clinical and experimental. 2012; 73(3):86-102. doi:10.1016/j.curtheres.2012.04.002 PMID: 24648596.
36. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrobial agents and chemotherapy. 2006; 50(6):2042-9. PMID: 16723564.
37. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrobial agents and chemotherapy. 2002; 46(8):2723-6. PMID: 12121967.
38. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid. Pharmacotherapy. 2001; 21(8):1010-3. PMID: 11718489.
39. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrobial agents and chemotherapy. 2006; 50(6):2042-9. PMID: 16723564.
40. Manyan DR, Arimura GK, Yunis AA. Chloramphenicol-induced erythroid suppression and bone marrow ferrochelatase activity in dogs. The Journal of laboratory and clinical medicine. 1972; 79(1):137-44. PMID: 5007558.
41. Parashar S, Rao R, Tikare SK, Tikare SS. Chloramphenicol induced reversible bone marrow suppression. A case report. Journal of postgraduate medicine. 1972; 18(2):90-2. PMID: 5037129.
42. Yunis AA. Chloramphenicol-induced bone marrow suppression. Seminars in hematology. 1973; 10 (3):225-34. PMID: 4577646.
43. Skripkin E, McConnell TS, DeVito J, Lawrence L, Ippolito JA, Duffy EM, et al. R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. Antimicrobial agents and chemotherapy. 2008; 52(10):3550-7. doi:10.1128/AAC.01193-07 PMID: 18663023.
44. Yan K, Madden L, Choudhry AE, Voigt CS, Copeland RA, Gontarek RR. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrobial agents and chemotherapy. 2006; 50(11):3875-81. PMID: 16940066.
45. Rajamuthiah R, Fuchs BB, Conery AL, Kim W, Jayamani E, Kwon B, et al. Repurposing Salicylanilide Anthelmintic Drugs to Combat Drug Resistant Staphylococcus aureus. PloS one. 2015; 10(4): e0124595. doi:10.1371/journal.pone.0124595 PMID: 25897961.
46. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillinresistant Staphylococcus aureus infections. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2009; 49(7):1072-9.
47. Appelbaum PC. Microbiology of antibiotic resistance in Staphylococcus aureus. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2007; 45 Suppl 3:S165-S70.
48. Huang V, Rybak MJ. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrobial agents and chemotherapy. 2005; 49(1):302-8. PMID: 15616309.
49. Drago L, De Vecchi E, Nicola L, Gismondo MR. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC infectious diseases. 2007; 7:111. PMID: 17888153.